0

Neuroblastoma: From Bench to Bedside Symposium Feb 16-18, 2012

Two meetings of great interest are back-to-back this month. Unfortunately NB Globe will not be able to report first-hand on the Pediatric Cancer Translational Genomics Conference Feb 6-8 but news from a science writer employed to report on this meeting will be available — see the agenda here: https://www.tgen.org/tpcg/agenda.cfm

Following this is an exciting meeting on neuroblastoma is taking place in Tubingen, Germany Feb 16-18, and thanks to our supportive friends, The Neuroblastoma Children’s Cancer Alliance UK, reports on this meeting from NB Globe are forth coming!  Anyone interested is invited to attend an informal debriefing in London on Sunday afternoon/evening February 19 in Gloucester Road/Piccadilly line tube station area (contact here for more information about the place and time).

Bios of the speakers are found at this link: http://www.neuroblastoma2012.com/Speakers.php

A preview of topics:

Wednesday, February 15 th , 2012

SIOPE Study Committee Meeting
Chair: Dr Penelope Brock, London, UK

Thursday, February 16 th , 2012

SIOPE Study Committee Meeting
Chair: Dr Penelope Brock, London, UK
Master Class in neuroblastoma
Pathology of neuroblastoma  
Ivo Leuschner, Kiel, Germany
Diagnostic imaging in neuroblastoma – what do we need Juergen F. Schaefer, Tübingen, Germany
Principles of chemotherapy in neuroblastoma Frank Berthold, Cologne, Germany
Staging systems for neuroblastoma Tom Monclair, Oslo, Norway
Open surgical approaches and the impact of gross total resections on outcome in neuroblastoma  Michael LaQuaglia, New York, NY, USA
Minimally invasive surgery in neuroblastoma (video session) Jörg Fuchs, Tübingen, Germany
Immunotherapy in neuroblastoma  Paul Sondel, Madison, WI, USA

Friday February 17 th , 2012

Session I: Pathology
Chairs: Angelika Eggert, Essen, Germany / Guido Seitz, Tübingen, Germany
Pathology of neuroblastoma Ivo Leuschner, Kiel, Germany 
Molecular subgrouping of neuroblastoma by Kogner, Stockholm, Sweden
Session II: Basic research, Biology and Genetics
Chairs: Frank Berthold, Cologne, Germany / Peter Ambros, Vienna, Austria
The way to personalized medicine approaches in neuroblastoma Angelika Eggert, Essen, Germany
Neuroblastoma tumor genetics in Manfred Schwab, Heidelberg, Germany
Minimal residual disease Peter Ambros, Vienna, Austria
High ALK receptor tyrosine kinase ALK expression prevail mutation as a determing factor of an unfavorable phenotype in primary neuroblastoma John Schulte, Essen, Germany 
Exon – level expression analysis for prediction of outcome and biological characterization of neuroblastoma Alexander Schramm, Essen, Germany  
Session III: Immunotherapy
Chairs: Rupert Handgretinger, Tuebingen, Germany / Paul Sondel, Madison, USA
Peptide antigen characterization for clinical immunotherapy studies Hans-Georg Rammensee, Tübingen, Germany 
Antibody dependent cell-mediated cytotoxicity of neuroblastoma clinical therapy as Paul Sondel, Madison, USA 
Antibody treatment for neuroblastoma – experience the Deutsch Thorsten Simon, Cologne, Germany
Current concepts and perspectives in immunotherapy of neuroblastoma Holger Lode, Greifswald, Germany
Anti-GD 2antibody treatment and haploidentical stem cell transplantation in neuroblastoma Peter Lang, Tübingen, Germany 
Session IV: Free Talks
Chairs: Per Kogner, Stockholm, Sweden / Holger Lode, Greifswald, Germany
Utilizing hemodynamic response imaging (HRI) for new anti – angiogenic treatment surveillance in a mouse model of neuroblastoma Chani Komar, Jerusalem, Israel
Differences in in vivo and in vitro binding of three GD2 – specific antibodies Julia Schmitt, Tübingen, Germany 
Thiotepa and melphalan-based single, tandem and triple high-dose therapy and autologous stem cell transplantation for high-risk neuroblastoma, Ulla Saarinen – Pihkala, Helsinki, Finland
Haploidentical stem cell transplantation for treatment of children with refractory neuroblastomaDesantes Kenneth, Madison, WI, USA 
Drug resistant neuroblastoma cell lines established from progressive disease are highly sensitive to killing by genetically engineered, GD2 – specific NK cells, Diana Seidel, Greifswald, Germany
Molecular characterization of a new anti – idiotype antibody for active immunotherapy in neuroblastoma Diana Brackish Rock, Greifswald, Germany
HDAC11 transcriptionally represses BMP4 to promote neuroblastoma malignancy Deubzer Hedwig, Heidelberg, Germany 
Expression of neuroendocrine transmitter substances in neuroblastoma You-Jung Bak, Frankfurt / Main, Germany
miR – 542 – 3p functions as a tumor suppressor in neuroblastoma by down regulating survivinKristina Kieckbusch, Essen, Germany 
Tumor – promoting and inhibiting functions of drug – induced senescent neuroblastoma cell linesSabine Taschner Mandl, Vienna, Austria 

Saturday February 18 th , 2012

Session V: Clinical Trials
Chairs: Joerg Fuchs, Tuebingen, Germany / Thorsten Simon, Cologne, Germany
Results from the trial Deutsch neuroblastoma Frank Berthold, Cologne, Germany 
Results from the trial HR-NBL1/SIOPEN Ruth Ladenstein, Vienna, Austria
Results from the COG neuroblastoma trials John Maris, Philadelphia, USA 
The International Neuroblastoma Risk Group Stratification System Tom Monclair, Oslo, Norway
Session VI: Surgery
Chairs: John Maris, Philadelphia, USA / Michael LaQuaglia, New York, USA
Surgical strategies for advanced neuroblastoma – The North American experience LaQuaglia Michael, New York, USA 
Surgery for high-risk neuroblastoma grandmothers of the abdominal cavity Jörg Fuchs, Tübingen, Germany 
Surgery for thoracic neuroblast grandma Dietrich von Schweinitz, Munich, Germany 
Located in the thoracic neuroblastoma – jugular junction January Godzinski, Wroclaw, Poland 
Does “Aggressive Surgical Resection” – improve survival for advanced stage III and IV neuroblastoma? - A systematic review and meta – analysis Paul Farrelly, Liverpool, UK   
Session VII: Radiology, Radiation Therapy, Nuclear Medicine, Genetics
Chairs: Ruth Ladenstein, Vienna, Austria / Tom Monclair, Oslo, Norway
Imaging for Neuroblastoma – from CT to PET-MRI: current strategies Juergen F. Schaefer, Tübingen, Germany 
Radiolabelled mIBG for diagnosis and therapy of neuroblastoma Roland Bares, Tübingen, Germany 
The role of radiotherapy in neuroblastoma: Established and novel approaches Beate Timmermann, Essen, Germany
Integration of host and tumor genetic information to identify key oncogenic pathways in neuroblastoma John Maris, Philadelphia, USA 


Filed in: Meetings

Share This Post

Leave a Reply

Submit Comment

© 2014 NB Globe ~ Neuroblastoma News. All rights reserved. | Contact Us